---
title: 'Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety
  results through week 96 from a phase 3 randomized trial'
date: '2024-05-11'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38734383/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240512181047&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Virologic and biochemical responses were maintained and/or
  increased with longer-term BLV therapy, including in those with suboptimal early
  virologic response. BLV monotherapy for CHD was safe and well tolerated through
  ...'
disable_comments: true
---
CONCLUSIONS: Virologic and biochemical responses were maintained and/or increased with longer-term BLV therapy, including in those with suboptimal early virologic response. BLV monotherapy for CHD was safe and well tolerated through ...